A Maximum-Use Trial of Ruxolitinib Cream in Adolescents and Adults with Atopic Dermatitis

ConclusionsUnder maximum-use conditions, ruxolitinib cream was generally well tolerated, with approximately one-third of patients experiencing treatment-emergent adverse events and few treatment-related adverse events. The mean steady-state plasma concentration of ruxolitinib was well below the level expected to affect bone marrow production of blood cells, with a small number of patients exhibiting higher plasma concentrations. In addition, ruxolitinib cream showed a high level of efficacy in patients with atopic dermatitis involving ≥ 25% affected body surface area.ClinicalTrials.gov IdentifierNCT03920852.
Source: American Journal of Clinical Dermatology - Category: Dermatology Source Type: research